VPS33A

Across TCGA pan-cancer cohorts, VPS33A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VPS33A data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VPS33A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VPS33A expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where VPS33A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.131	0.861	.001	18	view →
HNSC	OS	Median	IV	0.604	0.812	.022	11	view →
PDAC	OS	Median	All	0.451	0.305	.026	6	view →
GBM	DFS	Tertile	All	0.513	0.243	.015	5	view →
LUAD	DFS	Tertile	II,III,IV	0.322	0.669	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VPS33A–CCRCC (DFS)

Open the CCRCC breakdown →